Alector(ALEC.US)盘前暴跌近60%

Core Viewpoint - Alector's stock plummeted nearly 60% in pre-market trading following the announcement from GlaxoSmithKline that their collaborative experimental drug, latozinemab, failed to slow the progression of dementia, marking another setback in the development of potential dementia treatments [1] Company Summary - Alector experienced a significant decline in stock value, dropping close to 60% [1] - The failure of latozinemab represents a major setback for Alector in its efforts to develop effective treatments for dementia [1] Industry Summary - The announcement highlights ongoing challenges in the biotechnology sector, particularly in the development of drugs aimed at treating neurodegenerative diseases such as dementia [1] - The failure of another potential treatment underscores the high-risk nature of drug development in the biotech industry [1]